Stocks · News reference
Microsoft Increases Oversight of Data Center Projects Involving Nebius Group
Microsoft is reportedly increasing its oversight of certain data center projects, including those involving Nebius Group N.V., amid concerns over construction and permitting delays.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nebius Stock: The Bull Case, the Bear Case, and My Call Before Nov. 12
Nebius Group stock has fallen 47% from its June peak to around $152. The bull case rests on management's target of $7-9 billion annualized run-rate revenue by year-end 2026 (up from $3 billion in June), with the company demonstrating strong growth momentum. However, the bear case highlights massive capital expenditure needs ($20-25 billion in 2026) requiring significant external funding, customer concentration risk (3 customers = 59% of revenue), and reliance on share dilution and debt. The analyst recommends waiting for Q3 results on Nov. 12 to assess if the company remains on track for its targets before making an investment decision.
Citigroup Maintains Buy on Nebius Group, Lowers Price Target to $265
Citi Maintains Nebius Group with Buy Rating, Adjusts Price Target
Citi analyst Tyler Radke has maintained a Buy rating on Nebius Group (NBIS) while lowering the price target from $324 to $265.
CoreWeave, Peers Fall After Democrats Sweep Midterms; What it Means For Data Centers
CoreWeave and other data center stocks are trading lower Wednesday after Democrats won control of Congress in the midterm elections.
3 Nasdaq-100 Stocks That Can Double, According to Wall Street
Wall Street analysts identify three Nasdaq-100 stocks with potential to double based on median target prices: CoreWeave (140% upside) as a leading AI cloud provider with strong revenue growth but profitability concerns due to high debt; Nebius Group (100% upside) as an emerging AI cloud competitor with faster revenue growth but expensive valuation; and Alnylam Pharmaceuticals (100% upside) as an RNA interference therapy leader with an attractive valuation and promising pipeline.